Interní Med. 2013; 15(3-4): 105-109

Modern diagnosis and treatment of malignant lymphomas

MUDr.Robert Pytlík1, MUDr.Adéla Berková1,2,3, MUDr.Václav Ptáčník4
1 1. interní klinika &ndash, hematologie, 1. lékařská fakulta UK a Všeobecná fakultní nemocnice, Praha
2 Centrum nádorové cytogenetiky, Ústav lékařské biochemie a laboratorní diagnostiky, 1. lékařská fakulta UK

Non-Hodgkin´s lymphomas (NHL) are malignant diseases with rising incidence. On the other hand, most of them belong among the

best treatable cancers. Diagnostics and staging have currently improved especially due to immunohistochemistry, molecular biology

studies and positron emission tomography, however, for timely diagnosis, high index of suspicion and correctly performed sample

collection is essential. In most non-Hodgkin´s lymphomas, immunochemotherapy plays crucial role and has improved prognosis in

almost all types of B-lymphomas. Most of T-cell lymphomas have still dismal prognosis, however, these diseases are rather rare in

Czech population.

Keywords: lymphoma, positron emission tomography, chemotherapy, radiotherapy, immunotherapy

Published: March 20, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pytlík R, Berková A, Ptáčník V. Modern diagnosis and treatment of malignant lymphomas. Interní Med. 2013;15(3-4):105-109.
Download citation

References

  1. International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO press, Geneva, Switzerland, 2008.
  2. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/ Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16: 471-93. Go to original source... Go to PubMed...
  3. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86. Go to original source... Go to PubMed...
  4. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin´s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652-61. Go to original source... Go to PubMed...
  5. Sehn LH, Donadlson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-33. Go to original source... Go to PubMed...
  6. Siddharta G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma. A meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009 Mar 24; 2: 14. doi: 10.1186/1756-8722-2-14. Go to original source... Go to PubMed...
  7. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-31. Go to original source... Go to PubMed...
  8. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised control trial. Lancet 2011; 377: 42-51. Go to original source... Go to PubMed...
  9. Procházka V, Trněný M, Pytlík R, et al. Peripheral T-cell lymphoma, unspecified - the analysis of the data from the Czech Lymphoma Study Group. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151: 103-7. Go to original source... Go to PubMed...
  10. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-90. Go to original source... Go to PubMed...
  11. Thieblemont C, Delfau-Larue MH, Coiffier B. Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol 2012; 2012: 861060. doi: 10.1155/2012/861060. Epub 2012 Nov 20. Go to original source... Go to PubMed...
  12. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27: 1492-501. Go to original source... Go to PubMed...
  13. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190-6. Go to original source... Go to PubMed...
  14. Qi W, Spier C, Liu X, et al. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 2012 Nov 12. doi: pii: S0145-2126 (12)00429-8.10.1016/j.leukres.2012.10.017 [Epub ahead of print].




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.